Building a Functionally Relevant In Vitro Model of Alzheimer’s Disease with Patient-Derived iPSCs

The poster Building a Functionally Relevant In Vitro Model of Alzheimer’s Disease with Patient-Derived iPSCs presents Axol Bioscience’s approach to modeling AD using patient-derived iPSCs differentiated into key neural cell types.

Key highlights include:

• Patient Diversity:
  • iPSC lines from donors with APOE4 homozygous mutations and PSEN1 variants (L286V, M146L)
• Cell Types Generated:
  • Cortical neurons, astrocytes, and microglia
• Marker Validation:
  • ICC confirms expression of CTIP2, TUJ1, TBR1, CUX1, MAP2 (neurons); AQP4, EAAT2, A2B5, GFAP, Nestin (astrocytes); IBA1, P2RY12, TMEM119 (microglia)
• Functional Assays:
  • Phagocytosis of Aβ and MBP measured via pHrodo assay
  • AD lines show reduced clearance compared to healthy controls
• Transcriptomic Analysis:
  • TempO-Seq and GO enrichment reveal distinct pathway activation across cell types
  • Clustering analysis shows clear separation between iPSCs and differentiated cells
• Model Utility:
  • Supports “Clinical Trial in a Dish” approach
  • Enables mutation-specific drug screening and patient stratification

This model supports scalable, physiologically relevant AD research and therapeutic development.

Featured Axol Products:

• axoCells™ Cortical Neurons 
• axoCells™ Astrocytes – AD (APOE4/PSEN1) – ax0665
• axoCells™ Microglia – AD (APOE4/PSEN1) – ax0666
• axoServices™ Differentiation – (custom service)